Bioasis Technologies

Bioasis Technologies P/CF

P/CF (Price-to-Cash-Flow Ratio) of Bioasis Technologies (BIOAF) as of Oct 26, 2026.

P/CF

-0.00

YoY

-148.73%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Bioasis Technologies is 2022 -0.00 . P/CF (Price-to-Cash-Flow Ratio) of Bioasis Technologies was 2021 0.01 . It decreases by -148.73% lower compared to the previous year.

The Bioasis Technologies P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2015
-0.01 CAD
Jan 1, 2016
-0.01 CAD
Jan 1, 2017
-0.01 CAD
Jan 1, 2018
-0.00 CAD
Jan 1, 2019
-0.00 CAD
Jan 1, 2020
-0.00 CAD
Jan 1, 2021
0.01 CAD
Jan 1, 2022
-0.00 CAD
The Bioasis Technologies P/CF history
YEARP/CFYoY
-0.00-148.73%
0.01-286.21%
-0.00-2.09%
-0.00+13.73%
-0.00-66.13%
-0.01+22.99%
-0.01+31.69%
-0.01+40.15%
-0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Bioasis Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bioasis Technologies

All Key Metrics — Bioasis Technologies